首页 > 市场调查报告书 > 製药

肥胖症

市场调查报告书

商品编码

1899479

肥胖症治疗市场规模、份额及成长分析（按手术类型、药物类型、最终用户和地区划分）－2026-2033年产业预测

Obesity Treatment Market Size, Share, and Growth Analysis, By Surgery Type (Biliopancreatic diversion with Duodenal Switch (BPD/DS), Adjusting Gastric Banding), By Drug Type, By End User, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

全球肥胖治疗市场规模预计在 2024 年达到 97 亿美元，从 2025 年的 100.2 亿美元成长到 2033 年的 129.9 亿美元，在预测期（2026-2033 年）内复合年增长率为 3.3%。

随着医疗保健机构积极应对肥胖症盛行率及其相关健康风险的急剧上升，全球肥胖症治疗市场正在迅速扩张。肥胖与糖尿病、心血管疾病和多种癌症等严重密切相关，因此迫切需要创新的治疗方案。导致肥胖症流行的因素包括久坐不动的生活方式、不良的饮食习惯和遗传倾向。药物疗法，例如食慾抑制剂和促进能量消耗的药物，与减肥手术等医疗设备手术方案一起发挥重要作用。此外，旨在控制食量和以营养与运动为中心的身临其境型生活方式介入计画对于长期疗效也至关重要。在人们对肥胖症健康影响的认识不断提高的推动下，该市场为相关人员之间的技术进步、投资和合作提供了丰富的机会。

全球肥胖症治疗市场驱动因素

全球肥胖症发生率的不断上升是推动肥胖症治疗市场发展的主要因素。久坐不动的生活方式、不良的饮食习惯以及遗传倾向等因素进一步加剧了这一日益严重的健康危机。随着肥胖症相关健康风险的日益凸显，对有效治疗方案的需求也持续飙升。人们对肥胖症健康影响的认识不断提高，促使个人和医疗系统寻求可靠且创新的治疗方法，这进一步推动了肥胖症治疗产业的成长。因此，市面上有效治疗方案的研发和普及程度显着提高。

限制全球肥胖治疗市场的因素

全球肥胖治疗市场面临的主要障碍之一是肥胖相关治疗的保险覆盖范围有限或缺乏。保险公司通常会设定严格的条件，要求患者达到特定的BMI值或提供先前减重失败的证明，才能获得治疗核准。这种保险覆盖范围的不足限制了患者获得必要治疗的机会，最终削弱了肥胖管理工作的有效性。保险覆盖不足带来的挑战可能导致许多人无法获得必要的干预措施，从而加剧肥胖流行，并阻碍人群健康状况的改善。

全球肥胖症治疗市场趋势

全球肥胖治疗市场正经历着向个人化医疗的显着转变，这种转变将肥胖视为一种受遗传、代谢和生活方式因素影响的多面向疾病。基因组研究和生物标记识别的重大进展推动了这一转变，为个人化治疗策略铺平了道路。专业人士越来越关注精准医疗和标靶治疗，以应对每个人的独特特征，从而提高治疗效果和依从性。随着医疗服务提供者致力于优化治疗结果，个人化肥胖管理方法的整合有望推动市场创新和成长，为患者提供更有效的解决方案。

北美洲
- 美国
- 加拿大
欧洲
- 德国
- 西班牙
- 法国
- 英国
- 义大利
- 其他欧洲地区
亚太地区
- 中国
- 印度
- 日本
- 韩国
- 亚太其他地区
拉丁美洲
- 巴西
- 其他拉丁美洲地区
中东和非洲
- 海湾合作委员会国家
- 南非
- 其他中东和非洲地区

竞争资讯

前五大公司对比
主要企业的市场定位（2025 年）
主要市场参与者所采取的策略
近期市场趋势
公司市占率分析（2025 年）
主要企业公司简介
- 公司详情
- 产品系列分析
- 依业务板块进行公司股票分析
- 2023-2025年营收年比比较

主要企业简介

Novo Nordisk（Denmark）
Eli Lilly and Company（United States）
Roche（Switzerland）
GlaxoSmithKline（GSK）（United Kingdom）
AstraZeneca（United Kingdom）
Johnson & Johnson（United States）
Sanofi（France）
Pfizer（United States）
Amgen（United States）
Boehringer Ingelheim（Germany）
Medtronic（Ireland）
Altimmune（United States）
Viking Therapeutics（United States）
Structure Therapeutics（United States）
NovoCure（United States）
Arena Pharmaceuticals（United States）
Rhythm Pharmaceuticals（United States）
Zafgen（United States）
Vivus（United States）

结论与建议

简介目录

Product Code: SQMIG35A2358

Global Obesity Treatment Market size was valued at USD 9.7 Billion in 2024 and is poised to grow from USD 10.02 Billion in 2025 to USD 12.99 Billion by 2033, growing at a CAGR of 3.3% during the forecast period (2026-2033).

The global obesity treatment market is expanding rapidly as healthcare providers respond to the alarming rise in obesity prevalence and its related health risks. As obesity is linked to serious conditions like diabetes, cardiovascular diseases, and various cancers, there is an urgent demand for innovative treatment solutions. Factors contributing to this epidemic include sedentary lifestyles, poor dietary choices, and genetic predispositions. Pharmaceutical interventions, including appetite suppressants and medications that enhance energy expenditure, play a vital role, alongside surgical options such as bariatric procedures. Moreover, medical devices designed for portion control and immersive lifestyle programs centered on nutrition and exercise are essential for long-term success. Driven by heightened awareness of obesity's health impacts, this market presents ample opportunities for advancement, investment, and collaboration among stakeholders.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Obesity Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Obesity Treatment Market Segments Analysis

Global Obesity Treatment Market is segmented by Surgery Type, Drug Type, End User and region. Based on Surgery Type, the market is segmented into Biliopancreatic diversion with Duodenal Switch (BPD/DS), Adjusting Gastric Banding, Roux-en-Y Gastric Bypass, Sleeve gastrectomy and Endoscopic Procedures. Based on Drug Type, the market is segmented into Appetite suppressants, Combination drugs, Malabsorption and Satiety drugs. Based on End User, the market is segmented into Hospital, Clinics, Beauty institutions and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Obesity Treatment Market

The increasing worldwide incidence of obesity stands as a major catalyst for the obesity treatment market. Contributing factors like sedentary lifestyles, poor dietary choices, and genetic tendencies have exacerbated this escalating health crisis. As the associated health risks linked to obesity become more apparent, the demand for effective treatment solutions continues to surge. This heightened awareness of the medical implications of obesity propels both individuals and healthcare systems to seek reliable and innovative therapies, further stimulating growth within the obesity treatment sector. As a result, the market is witnessing a significant enhancement in the development and availability of effective treatment options.

Restraints in the Global Obesity Treatment Market

A significant barrier in the Global Obesity Treatment market is the limited or absent insurance coverage for obesity-related therapies. Insurance companies often impose stringent criteria, necessitating that patients achieve certain BMI levels or show evidence of unsuccessful prior weight loss methods before approval for treatment. This lack of extensive insurance support restricts access to essential therapies, ultimately undermining the effectiveness of obesity management efforts. The challenges posed by inadequate coverage can prevent many individuals from receiving the necessary interventions, thereby exacerbating the prevalence of obesity and hindering overall health improvements within the population.

Market Trends of the Global Obesity Treatment Market

The Global Obesity Treatment market is witnessing a notable trend towards personalized medicine, recognizing obesity as a multifaceted condition shaped by genetic, metabolic, and lifestyle factors. This shift is fueled by significant advancements in genomic research and biomarker identification, paving the way for customized treatment strategies. Professionals are increasingly focusing on precision medications and targeted therapies that address the unique characteristics of each individual, enhancing treatment efficacy and adherence. As healthcare providers look to optimize outcomes, the integration of tailored approaches into obesity management is expected to drive innovation and growth within the market, offering patients more effective solutions.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Advancement

Global Obesity Treatment Market Size by Surgery Type & CAGR (2026-2033)

Market Overview
Biliopancreatic diversion with Duodenal Switch (BPD/DS)
Adjusting Gastric Banding
Roux-en-Y Gastric Bypass
Sleeve gastrectomy
Endoscopic Procedures

Global Obesity Treatment Market Size by Drug Type & CAGR (2026-2033)

Market Overview
Appetite suppressants
Combination drugs
Malabsorption
Satiety drugs

Global Obesity Treatment Market Size by End User & CAGR (2026-2033)

Market Overview
Hospital
Clinics
Beauty institutions
Others

Global Obesity Treatment Market Size & CAGR (2026-2033)

North America (Surgery Type, Drug Type, End User)
- US
- Canada
Europe (Surgery Type, Drug Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Surgery Type, Drug Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Surgery Type, Drug Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Surgery Type, Drug Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Novo Nordisk (Denmark)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline (GSK) (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Medtronic (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Altimmune (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Viking Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Structure Therapeutics (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
NovoCure (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Arena Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Rhythm Pharmaceuticals (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Zafgen (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vivus (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments